+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Antifungal Drugs Market Size, Share & Trends Analysis Report By Drug Class (Azoles, Echinocandins, Polyenes, Allyamines), By Indication (Dermatophytosis, Aspergillosis, Candidiasis), and Segment Forecasts, 2018 - 2025

  • ID: 4751747
  • Report
  • 100 pages
  • Grand View Research
1 of 3

FEATURED COMPANIES

  • Abbott
  • Astellas Pharma, Inc.
  • Bayer AG
  • GlaxoSmithKline plc
  • Glenmark
  • Merck & Co., Inc.
  • MORE
The global antifungal drugs market size is expected to reach USD 12.7 billion by 2025, at a CAGR of 1.5% during the forecast period. Increasing incidence of fungal infections worldwide is the key factor stoking the growth of the market. In addition, rise in adoption of immunosuppressive and antineoplastic agents, prosthetic devices and grafts, and broad-spectrum antibiotics has resulted in increased incidence of fungal infections in recent years.

According to statistics published by the Centers of Disease Control and Prevention in 2017, it has been estimated that every year, nearly 220,000 new individuals are affected by cryptococcal meningitis, which is a brain infection and has resulted in 181,000 deaths per year around the world. Most of the deaths were reported in sub-Saharan Africa, due to high prevalence of HIV/AIDS. This indicates the potential demand for antifungal drugs due to high prevalence of mycological infections around the globe.

As aged people are more prone to infectious diseases and chronic conditions, including HIV and cancer, rise in geriatric population worldwide is likely to stir up the demand for antifungals to treat opportunistic fungal infections. The demand for fungistatic agents is estimated to remain strong through 2025 due to mounting cases of fungal infections that are difficult to diagnose, yielding high mortality and morbidity rates.

Further key findings from the study suggest:
  • Several types of fungicidal preparations, such as creams, sprays, tablets, & injections, are available. Increasing adoption of these products is anticipated to drive the market during the forecast period
  • The echinocandins segment is anticipated to exhibit lucrative growth owing to their cell wall-specific fungicidal property coupled with their broad-spectrum activity against Aspergillus and Candida species without cross-resistance risks
  • The candidiasis indication segment is expected to witness the fastest CAGR over the forecast period due to increasing drug resistance of the Candida species to Azoles
  • North America held the largest market share in 2017. The growth of the market can be attributed to higher awareness levels pertaining to treatment of fungal infection and presence of a large target population
  • Asia pacific is projected to register the fastest growth during the forecast period due to improving healthcare facilities coupled with rising government initiatives to create awareness of infectious diseases among the population
  • Companies are focusing on development of effective therapeutic agents for treatment of systemic fungal infections in immune-compromised patients
  • Numerous ongoing public-private partnership agreements in the pharmaceutical industry for development of novel therapeutics is poised to provide the market with lucrative growth opportunities. For instance, Astellas Pharma partnered with Vical Incorporated for the development of VL-2397, an antifungal drug for the treatment of pulmonary aspergillus.

Please note: This product will be delivered within 48 business hours after receipt of order.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Abbott
  • Astellas Pharma, Inc.
  • Bayer AG
  • GlaxoSmithKline plc
  • Glenmark
  • Merck & Co., Inc.
  • MORE
Chapter 1 Research Methodology & Scope
1.1 Region Wise Market Calculation
1.1.1 Region Wise Market: Base Estimates
1.1.2 Country share estimation
1.1.3 Global Market: CAGR Calculation
1.2 Region based segment share calculation
1.3 List of Secondary Sources

Chapter 2 Executive Summary
2.1 Market Snapshot

Chapter 3 Antifungal Drugs Market Variables, Trends & Scope
3.1 Market Segmentation & Scope
3.2 Market Driver Analysis
3.2.1 Increasing incidence of fungal infections
3.2.2 Rising R & D pertaining to the development of novel drugs
3.2.3 Increase in awareness
3.3 Market Restraint Analysis
3.3.1 Increasing resistance to antifungal drugs
3.3.2 Presence of generic competition
3.4 Penetration & Growth Prospect Mapping
3.5 Antifungal Drugs - SWOT Analysis, By Factor (political & legal, economic and technological)
3.6 Industry Analysis - Porter’s
3.7 Pricing Analysis
3.8 Competitive Landscape
3.9 Pipeline Analysis

Chapter 4 Antifungal Drugs Market Drug Class Estimates & Trend Analysis
4.1 Antifungal Drugs Market: Drug Class Movement Analysis
4.2 Azoles
4.2.1 Azoles market, 2014 - 2025 (USD Million)
4.2.2. Voriconazole (Vfend)
4.2.1.1 Voriconazole (Vfend) market, 2014 - 2025 (USD Million)
4.2.3 Posaconazole (Noxafil)
4.2.3.1 Posaconazole (Noxafil) market, 2014 - 2025 (USD Million)
4.2.4 Posaconazole (Noxafil)
4.2.4.1 Clotrimazole (Canesten) market, 2014 - 2025 (USD Million)
4.2.5 Isavuconazole (CRESEMBA)
4.2.5.1 Isavuconazole (CRESEMBA) market, 2014 - 2025 (USD Million)
4.2.6 Isavuconazole (CRESEMBA)
4.2.6.1 Others market, 2014 - 2025 (USD Million)
4.3 Echinocandins
4.3.1 Echinocandins market, 2014 - 2025 (USD Million)
4.3.2 Caspofungin (Cancidas)
4.3.2.1 Caspofungin (Cancidas) market, 2014 - 2025 (USD Million)
4.3.3 Micafungin (Mycamine/ Funguard)
4.3.3.1 Micafungin (Mycamine/ Funguard) market, 2014 - 2025 (USD Million)
4.3.4 Others
4.3.4.1 Others market, 2014 - 2025 (USD Million)
4.4 Polyenes
4.4.1 Polyenes market, 2014 - 2025 (USD Million)
4.4.2 Amphotericin (AmBisome)
4.4.2.1 Amphotericin (AmBisome) market, 2014 - 2025 (USD Million)
4.4.3 Others
4.4.3.1 Others market, 2014 - 2025 (USD Million)
4.5 Allylamines
4.5.1 Allylamines market, 2014 - 2025 (USD Million)
4.5.2 Terbinafine (Lamisil)
4.5.2.1 Terbinafine (Lamisil) market, 2014 - 2025 (USD Million)
4.5.3 Others
4.5.3.1 Others market, 2014 - 2025 (USD Million)
4.6 Others
4.6.1 Others market, 2014 - 2025 (USD Million)

Chapter 5 Antifungal Drugs Market Indication Estimates & Trend Analysis
5.1 Antifungal Drugs Market: Indication Movement Analysis
5.2 Dermatophytosis
5.2.1 Dermatophytosis market, 2014 - 2025 (USD Million)
5.3 Aspergillosis
5.3.1 Aspergillosis market, 2014 - 2025 (USD Million)
5.4 Candidiasis
5.4.1 Candidiasis market, 2014 - 2025 (USD Million)
5.4.2 Invasive Candidiasis
5.4.2.1 Invasive candidiasis market, 2014 - 2025 (USD Million)
5.4.3 Vulvovaginal Candidiasis (VVC)
5.4.3.1 VVC market, 2014 - 2025 (USD Million)
5.4.4 Mouth/Throat/Esophageal Candidiasis
5.4.4.1 Mouth/throat/oesophageal candidiasis market, 2014 - 2025 (USD Million)
5.4.5 Other candida infections
5.4.5.1 Other candidal infections market, 2014 - 2025 (USD Million)
5.5 Others
5.5.1 Others market, 2014 - 2025 (USD Million)

Chapter 6 Antifungal Drugs Market Regional Estimates & Trend Analysis, by Drug Class and Indications
6.1 Antifungal drugs market share by region, 2017 & 2025
6.2 North America
6.2.1 North America antifungal drugs market, 2014 - 2025 (USD Million)
6.2.2 U.S.
6.2.2.1 U.S. antifungal drugs market, 2014 - 2025 (USD Million)
6.2.3 Canada
6.2.3.1 Canada antifungal drugs market, 2014 - 2025 (USD Million)
6.3 Europe
6.3.1 Europe antifungal drugs market, 2014 - 2025 (USD Million)
6.3.2 U.K.
6.3.2.1 U.K. antifungal drugs market, 2014 - 2025 (USD Million)
6.3.3 Germany
6.3.3.1 Germany antifungal drugs market, 2014 - 2025 (USD Million)
6.4 Asia Pacific
6.4.1 Asia Pacific antifungal drugs market, 2014 - 2025 (USD Million)
6.4.2 Japan
6.4.2.1 Japan antifungal drugs market, 2014 - 2025 (USD Million)
6.4.3 China
6.4.3.1 China antifungal drugs market, 2014 - 2025 (USD Million)
6.4.4 India
6.4.4.1 India antifungal drugs market, 2014 - 2025 (USD Million)
6.5 Latin America
6.5.1 Latin America antifungal drugs market, 2014 - 2025 (USD Million)
6.5.2 Brazil
6.5.2.1 Brazil antifungal drugs market, 2014 - 2025 (USD Million)
6.5.3 Mexico
6.5.3.1 Mexico antifungal drugs market, 2014 - 2025 (USD Million)
6.6 MEA
6.6.1 MEA antifungal drugs market, 2014 - 2025 (USD Million)
6.6.2 South Africa
6.6.2.1 South Africa antifungal drugs market, 2014 - 2025 (USD Million)

Chapter 7 Competitive Landscape
7.1 Strategy Framework
7.2 Market Participation Categorization
7.3 Company Profiles
7.3.1 Novartis AG
7.3.1.1 Company overview
7.3.1.2 Financial performance
7.3.1.3 Product benchmarking
7.3.1.4 Strategic initiatives
7.3.2 Pfizer, Inc.
7.3.2.1 Company overview
7.3.2.2 Financial performance
7.3.2.3 Product benchmarking
7.3.2.4 Strategic initiatives
7.3.3 Bayer AG
7.3.3.1 Company overview
7.3.3.2 Financial performance
7.3.3.3 Product benchmarking
7.3.3.4 Strategic initiatives
7.3.4 Sanofi
7.3.4.1 Company overview
7.3.4.2 Financial performance
7.3.4.3 Product benchmarking
7.3.5 Merck & Co., Inc.
7.3.5.1 Company overview
7.3.5.2 Financial performance
7.3.5.3 Product benchmarking
7.3.5.4 Strategic initiatives
7.3.6 GlaxoSmithKline plc
7.3.6.1 Company overview
7.3.6.2 Financial performance
7.3.6.3 Product benchmarking
7.3.6.4 Strategic initiatives
7.3.7 Abbott
7.3.7.1 Company overview
7.3.7.2 Financial performance
7.3.7.3 Product benchmarking
7.3.7.4 Strategic initiatives
7.3.8 Glenmark
7.3.8.1 Company overview
7.3.8.2 Financial performance
7.3.8.3 Product benchmarking
7.3.8.4 Strategic initiatives
7.3.9 Enzon Pharmaceuticals, Inc.
7.3.9.1 Company overview
7.3.9.2 Financial performance
7.3.9.3 Product benchmarking
7.3.10 Astellas Pharma, Inc.
7.3.10.1 Company overview
7.3.10.2 Financial performance
7.3.10.3 Product benchmarking
7.3.10.4 Strategic initiatives
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Novartis AG
  • Pfizer, Inc.
  • Bayer AG
  • Sanofi
  • Merck & Co., Inc.
  • GlaxoSmithKline plc
  • Abbott
  • Glenmark
  • Enzon Pharmaceuticals, Inc.
  • Astellas Pharma, Inc.
Note: Product cover images may vary from those shown
Adroll
adroll